Previous 10 | Next 10 |
Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023 PDUFA goal date of January 3, 2024 set by FDA for cosibelimab to treat metastatic or locally advanced cutaneous squamous cell carcinoma MIAMI, May 15, 2023 (G...
2023-05-12 09:51:26 ET Avenue Therapeutics press release ( NASDAQ: ATXI ): Q1 GAAP EPS of -$1.37 misses by $1.24 . For further details see: Avenue Therapeutics GAAP EPS of -$1.37 misses by $1.24
MIAMI, May 12, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported finan...
MIAMI, April 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced th...
2023-04-18 10:43:23 ET Avenue Therapeutics ( NASDAQ: ATXI ) was trading around +4% on Tuesday after reporting progress in its efforts to secure approval for a Phase 3 clinical trial of its intravenous Tramadol. The drug developer noted that the FDA was largely in agreeme...
MIAMI, April 17, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today ann...
2023-04-04 08:16:25 ET Butterfly Network ( BFLY ) +22% gets FDA nod for AI-enabled lung tool. Bullfrog AI Holdings ( BFRG ) +24% Announces Exclusive, Worldwide Licensing Agreement with Johns Hopkins’ Applied Physics Laboratory for Patented AI Technology. ...
2023-03-31 00:51:41 ET Avenue Therapeutics press release ( NASDAQ: ATXI ): FY GAAP EPS of -$1.63. As of December 31, 2022, our cash and cash equivalents totaled $6.7 million, compared to $3.8 million at December 31, 2021, an increase of $2.9 million. For further deta...
Fortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous...
MIAMI, March 30, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today rep...
News, Short Squeeze, Breakout and More Instantly...
Avenue Therapeutics Inc. Company Name:
ATXI Stock Symbol:
NASDAQ Market:
Avenue Therapeutics Inc. Website:
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the ...
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutica...